Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Abbott Expects Prevacid Growth Of 25% Despite Looming PPI Competition

Jul 19 1999

• By The Pink Sheet

Related Content

Alza Brings Ditropan XL To Abbott As Near-Term Project In $7.3 Bil. Merger

Jun 28 1999

Abbott Norvir Returns To Market Via Contract Manufacturer

Jul 05 1999

Abbott Abbokinase "Dear Doctor" Letter Draws Warning From FDA

Mar 29 1999

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window